Implications for HIV elimination by 2030 of recent trends in undiagnosed
  infection in England: an evidence synthesis by Presanis, Anne M et al.
Implications for HIV elimination by 2030 of
recent trends in undiagnosed infection in
England: an evidence synthesis
Anne M Presanis1,*, Peter Kirwan2, Ada Miltz3,2, Sara Croxford2,
Ross Harris2, Ellen Heinsbroek2, Chris Jackson1, Hamish
Mohammed2, Alison Brown2, Valerie Delpech2, O Noel Gill2, and
Daniela De Angelis1,2
1Medical Research Council Biostatistics Unit, University of
Cambridge
2Public Health England
3Institute of Global Health, University College London
*
Corresponding author
December 17, 2019
1
ar
X
iv
:1
91
2.
07
31
0v
1 
 [s
tat
.A
P]
  1
6 D
ec
 20
19
Abstract
Background: A target to eliminate Human Immuno-deficiency Virus (HIV) transmis-
sion in England by 2030 was set in early 2019. Estimates of recent trends in HIV
prevalence, particularly the number of people living with undiagnosed HIV, by exposure
group, ethnicity, gender, age group and region, are essential to monitor progress towards
elimination.
Methods: A Bayesian synthesis of evidence from multiple surveillance, demographic
and survey datasets relevant to HIV in England is employed to estimate trends in: the
number of people living with HIV (PLWH); the proportion of these people unaware of
their HIV infection; and the corresponding prevalence of undiagnosed HIV. All estimates
are stratified by exposure group, ethnicity, gender, age group (15-34, 35-44, 45-59, 60-74),
region (London, outside London) and year (2012-2017).
Findings: The total number of PLWH aged 15-74 in England increased from 82,400
(95% credible interval, CrI, 78,700 to 89,100) in 2012 to 89,500 (95% CrI 87,400 to 93,300)
in 2017. The proportion diagnosed steadily increased from 84% (95% CrI 77 to 88%) to
92% (95% CrI 89 to 94%) over the same time period, corresponding to a halving in the
number of undiagnosed infections from 13,500 (95% CrI 9,800 to 20,200) to 6,900 (95%
CrI 4,900 to 10,700). This decrease is equivalent to a halving in prevalence of undiagnosed
infection and is reflected in all sub-groups of gay, bisexual and other men who have sex
with men and most sub-groups of black African heterosexuals. However, decreases were
not detected for some sub-groups of other ethnicity heterosexuals, particularly outside
London.
Interpretation: In 2016, the Joint United Nations Programme on HIV/ AIDS target
of diagnosing 90% of people living with HIV was reached in England. To achieve HIV
elimination by 2030, current testing efforts should be enhanced to address the numbers
of heterosexuals living with undiagnosed HIV, especially outside London.
1 Introduction
Early diagnosis of Human Immuno-deficiency Virus (HIV) infection and access to anti-
retroviral therapy (ART) can prevent onward transmission1. Regular assessment of the
burden of HIV is essential for evaluation of public health policies aimed at reducing
transmission, such as “Treatment as Prevention (TasP)”2–4 and HIV pre-exposure pro-
phylaxis (PrEP)5. Knowledge of the number and proportion of HIV infections remaining
undiagnosed is crucial for monitoring progress towards elimination of HIV transmission
by 20303. Since undiagnosed cases are inherently unobservable, these quantities must
be estimated.
Annual United Kingdom (UK) estimates of HIV prevalence, both diagnosed and undiag-
nosed, the number of people living with HIV (PLWH) and the proportions of infections
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that are diagnosed are published6 for gay, bisexual and other men who have sex with
men (MSM), people who inject drugs (PWID), and heterosexual individuals of both
black African and other ethnicity (as self-reported to the UK Census of 20117). The es-
timates are the yardstick for measuring the UK’s progress towards the first Joint United
Nations Programme on HIV/AIDS (UNAIDS) 90-90-90 target, i.e. 90% of HIV infections
diagnosed, and for informing HIV testing guidelines8;9 and prevention campagins10;11.
Since 2005, these estimates of HIV prevalence, seen as cross-sectional “snapshots” of
the state of the epidemic, have been derived through a “Multi-Parameter Evidence Syn-
thesis (MPES)”, a statistical approach combining and triangulating multiple sources of
surveillance and survey data12;13. Data on exposure group sizes, numbers diagnosed
and in care, and HIV prevalence from prevalence surveys and testing data, are synthe-
sised to estimate the undiagnosed fraction. As both the epidemic and the available data
sources have changed over time6, the MPES model has also evolved structurally since
its creation, to make greater and more efficient use of the available data.
This paper presents a major extension to our MPES model that integrates sequential
cross-sectional estimates to produce trends (with credible intervals) from 2012-2017 in
HIV prevalence and the number undiagnosed, by route of probable exposure (exposure
group), ethnicity, gender, age and region.
2 Methods
The adult population of England in the years 2012 to 2017 was stratified by exposure
group and ethnicity (MSM; PWID; black African heterosexuals; other ethnicity hetero-
sexuals); gender (men, women); age (15-34, 35-44, 45-59, 60-74); and region (London,
England outside London). The MSM and heterosexual exposure groups are further sub-
divided by whether or not they had attended a sexual health clinic in the last year for a
sexually transmitted infection (STI)-related need (“recent clinic attendee”). PWID are
stratified by whether or not they had injected drugs in the last year.
2.1 Multi-parameter evidence synthesis
To estimate HIV prevalence in each stratum, data are combined with prior assumptions,
in a Bayesian model that encodes the relationships between the data from each source
and the quantities to be estimated. The MPES approach12;13 consists of: defining the
key quantities (‘basic parameters’) to be estimated, with any prior knowledge of these
quantities summarised in a prior distribution; relating mathematically the quantities
(‘functional parameters’) directly informed by each data source to the basic parameters,
defining the likelihood of the data ; updating the prior distribution with our current
knowledge, summarised by the likelihood, to obtain a posterior distribution of all basic
and functional parameters, that summarises all uncertainty in both data and param-
eters. Any unobserved functional parameters of interest are also derived as functions
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of the basic parameters. This method ensures that resulting estimates are consistent
with all included data and model assumptions. We use Markov chain Monte Carlo to
draw samples from the posterior distribution, summarised by their median and a 95%
credible interval (credible interval (CrI)) defined by the 2.5 and 97.5 percentiles. Poste-
rior probabilities of either an increase or decrease over 2012-2017 in each outcome are
also calculated, as the proportion of posterior samples that are greater/smaller in 2017
compared to 2012. All analyses were carried out in R version 3.4.4, rstan and Stan14.
2.2 Model
We estimate three basic parameters for each stratum asrt defined by age group a, gender
s, region r and year t:
ρagsrt the proportion of the population in stratum asrt who are in exposure group g;
piagsrt HIV prevalence in stratum agsrt;
δagsrt the proportion of HIV infections in stratum agsrt that are diagnosed.
Given knowledge of these three basic parameters per stratum, any functional parameter
can be derived by defining it in terms of the basic parameters. The key functional
parameters are: the number of PLWH in each stratum, Nasrtρagsrtpiagsrt, where Nasrt
is the total population in stratum asrt, obtained from Office for National Statistics
(ONS) data; the number of undiagnosed infections, Nasrtρagsrtpiagsrt (1− δagsrt); and
the corresponding prevalence of undiagnosed infection, uagsrt = piagsrt (1− δagsrt).
2.3 Data and model assumptions
A substantial range of evidence is available in England to inform both exposure group
sizes and HIV prevalence, either directly or indirectly. Here we summarise the data and
their relationships to the parameters, while full details and a schematic diagram of the
model are given in the Appendix.
Group sizes Estimates of the size of the total population of England, by age, gender
and region strata , are available from the ONS, for each year15. The 2011 Census7
provides information on the proportions of the population self-reporting their ethnicity
(black African or any other ethnicity). These proportions are applied to the heterosexual
(non-MSM, non-PWID) group each year, to derive the annual distributions by ethnicity
of the heterosexual groups.
Survey-weighted estimates of the proportion of men who are MSM, by age and region,
are available from the National Survey of Sexual Attitudes and Lifestyles (NATSAL), a
national stratified probability sample from 201116.
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Information on PWID population sizes, both current and ex, is available from previous
studies, based on data from 2005-201217–19. Group sizes are therefore estimated for
2012, and are assumed not to change over time.
The sizes of the sub-groups of MSM and heterosexuals by ethnicity who have attended
a sexual health service (SHS) for a STI-related need in the last year, for each year 2012-
2017, are directly available from the GUMCAD STI surveillance system, a disaggregated,
pseudonymised data return submitted by all commissioned SHSs across England20.
Table 2 of the Appendix gives details of the group size parameters, their prior distribu-
tions or functional forms, and which datasets inform them.
Prevalence in clinic-attending groups The SHS data provide indirect evidence on
HIV prevalence, both diagnosed and undiagnosed, in the clinic-attending groups for
each year 2012-2017. Four components of HIV prevalence can be derived from the clinic
data combined with model assumptions: previously diagnosed prevalence (gagsrt1); newly
diagnosed prevalence (gagsrt2); prevalence of undiagnosed infection in those not offered
a HIV test (gagsrt3); and prevalence of undiagnosed infection in those opting out of a
HIV test (gagsrt4) (Table 3 of the Appendix). The diagnosed components are directly
observed, whereas the undiagnosed prevalences are estimated by relating them to newly
diagnosed prevalence.
Undiagnosed prevalence in MSM The Gay Men’s Sexual Health Survey (GMSHS)21
samples MSM at community venues in London every 2-3 years. Participants are offered
a HIV test and asked about recent sexual health service attendance and any previous
HIV diagnosis. Since GMSHS participants may be higher risk than average MSM, this
source provides over-estimates of HIV prevalence in all MSM. The data are therefore
used indirectly, to inform the odds ratio of (previously) undiagnosed prevalence in recent
clinic-attending vs non-clinic-attendingMSM (Table 3 of the Appendix).
Prevalence and proportion diagnosed in PWID The Unlinked Anonymous Monitoring
(UAM)22 annual survey of PWID recruits attendees at needle exchanges, methadone
treatment and other drug services and involves a (self-reported) questionnaire and dried
blood spot, which is tested for HIV antibodies. The survey provides information on both
HIV prevalence, piagsrt, and the proportion of PWID who have ever had a HIV diagnosis,
δagsrt, for each year 2012-2017. The sampled population is assumed to represent current
PWID.
For the ex-PWID group, we assume their stratum-specific proportion diagnosed is larger
than for current PWID (Table 3 of the Appendix).
Previously undiagnosed prevalence in women The National Study of HIV in Preg-
nancy and Childhood (NSHPC)23 is an annual register of all HIV diagnoses among preg-
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nant women. The observed number of diagnoses occurring during current pregnancies
are combined with data from ONS on the annual number of live births24, to indirectly
inform previously undiagnosed prevalence in non-PWID women under 45 years of age
(Table 4 of the Appendix), stratified by ethnicity, age and region.
Proportion diagnosed in black African heterosexuals The African Health and Sex
Survey (AHSS)25, carried out across England in 2014, provides information on the pro-
portion of African PLWH who self-report ever having had a HIV test, θasrt. As this
proportion does not directly inform proportions aware of their infection status, we in-
stead use the data indirectly, to inform the male-to-female odds ratio of the proportion
diagnosed (Table 4 of the Appendix).
Prevalence in the lowest risk group The National Health Service Blood and Trans-
plant (NHSBT) and Public Health England (PHE) carry out blood-borne virus testing
among blood donors, a population considered at very low risk of HIV infection, by gen-
der, region and age26. The HIV prevalence in blood donors, pi
(BD)
asrt , from the NHSBT
data are therefore used indirectly, to inform the male-to-female odds ratio of prevalence
in heterosexuals who are not recent clinic attendees (Table 4 of the Appendix).
Numbers diagnosed The HIV/AIDS Reporting System (HARS)27 is a comprehensive
surveillance system recording all new HIV diagnoses, as well as regular follow-up reports
on the clinical status of all diagnosed HIV-positive patients attending HIV outpatient
services for clinical care. Due to the very high retention in care of HIV patients in
the UK, the HARS data provide a complete yearly snapshot of the number of people
living with diagnosed HIV in the UK, by ethnicity, age, gender, region and year; as well
as the probable HIV exposure group distribution of these individuals (Table 5 of the
Appendix).
Borrowing strength across strata As the spread of available data across different strata
is uneven, we “borrow strength” from exposure-ethnicity-gender-age-region-year strata
with more data to smooth and increase precision in estimates of both HIV prevalence
piagsrt and the proportion diagnosed δagsrt for strata with fewer data sources. This is
achieved via a hierarchical random effects model that assumes that the log-odds ra-
tios of prevalence and proportion diagnosed in non-clinic-attending groups versus clinic-
attending groups might plausibly be thought similar, but not exactly equal, across strata.
Smoothing of trends in the log-odds ratios across years is achieved by also linking years
hierarchically.
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3 Results
The estimated number of PLWH in England aged 15-74 who were unaware of their
infection decreased from 13,500 (95% CrI 9,800 to 20,200) in 2012 to 6,900 (95% CrI
4,900 to 10,700) in 2017, posterior probability of a decrease p = 0.992, Table 1). This
decrease corresponded to a halving in the prevalence of undiagnosed infection from 0.34
(95% CrI 0.25 to 0.51) to 0.17 (95% CrI 0.12 to 0.26) per 1,000 population over the
five-year period. The decreases in numbers undiagnosed and undiagnosed prevalence
are notably greater in London than outside London (Table 1), demonstrated by the
consistently lower posterior probabilities p of a decrease. An increase in the number
of people living with diagnosed HIV resulted in the total number of PLWH increasing
from 82,400 (95% CrI 78,700 to 89,100) to 89,500 (95% CrI 87,400 to 93,300, p = 0.978)
in 2012-2017. The percentage diagnosed in the overall population therefore steadily
increased from 84% (95% CrI 77 to 88%) in 2012 to 92% (95% CrI 89 to 94%) in 2017,
reaching the UNAIDS 90% diagnosed target in 2016, and even earlier in 2013 for black
African heterosexuals (Figure 1).
A closer look at each sub-group reveals considerable variability in the pace of reduction
of undiagnosed infections (Table 1 and Figure 5 of the Appendix). While the 90%
target was achieved for most sub-groups by 2017, including both black African and
other ethnicity heterosexuals overall, the target has yet to be reached for other ethnicity
heterosexuals outside London who were recent clinic attendees. Moreover, there is less
evidence of an increase in the percentage diagnosed for this sub-group, as reflected by
the uncertainty in the estimates of the number unaware of their HIV infection (Figure
2). In total the numbers of other ethnicity heterosexuals living with undiagnosed HIV
reduced from 2,300 (95% CrI 1,700 to 4,000) to 1,600 (95% CrI 1,100 to 3,200, p = 0.857)
over 2012-2017 – with a corresponding drop in prevalence of undiagnosed infection from
0.059 (95% CrI 0.044 to 0.104) to 0.040 (95% CrI 0.027 to 0.082) per 1,000 population
(Table 1). However, such a decrease was not discernible in the two older age groups
outside London, particularly in those who were not clinic attendees (Table 2). Indeed,
in general, posterior probabilities of a decrease were lower for those who had not recently
attended a clinic than for those who had. Despite evidence for decreases in the numbers
of undiagnosed PLWH among clinic-attending other ethnicity heterosexuals, in terms of
undiagnosed prevalence (Table 2), the rates remained much larger for clinic-attendees
than for non-attendees.
Progress in reducing the undiagnosed pool of infection among black African heterosexuals
was more evident than for other heterosexuals (Figure 3), particularly in London. In
total, the decrease in black African heterosexuals unaware of their HIV infection was
pronounced over 2012-2017, from 2,700 (95% CrI 2,200 to 3,400) to 1,200 (95% CrI 1,000
to 1,500, p = 1), corresponding to a halving in the prevalence of undiagnosed infection
from 4.0 (95% CrI 3.3 to 4.9) to 1.7 (95% CrI 1.4 to 2.2) per 1,000 population (Table 1).
However, for the sub-group of clinic-attending black African heterosexuals aged 45-59
outside London, there was little evidence of a decrease in numbers undiagnosed (Figure
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3, p = 0.541). In contrast, the size of this 45-59 sub-group increased over the same time
period, from 3,200 (95% CrI 3,000 to 3,300) to 4,900 (95% CrI 4,800 to 5,000) attending
a clinic for STI-related needs. Taking this change in denominator into account, the
decrease in prevalence of undiagnosed infection in this group was estimated to be from
46 (95% CrI 27 to 76) to 29 (95% CrI 17 to 47) per 1,000 population over 2012-2017.
The decrease in numbers undiagnosed was notable in all sub-groups of MSM (Figure 4),
with the total more than halving from 8,100 (95% CrI 4,700 to 14,800) in 2012 to 3,800
(95% CrI 2,100 to 7,300) in 2017 (p = 0.965, Table 1). The corresponding prevalence
of undiagnosed infection dropped from 16.0 (95% CrI 9.3 to 28.8) to 7.2 (95% CrI 3.9
to 13.8) per 1,000 population. Also, the decrease was more pronounced for all MSM, in
London (p = 0.988) compared to outside London (p = 0.854, Figure 4). The numbers
undiagnosed were largest, but also most uncertain, amongst the 15-34 age group, with
posterior probabilities of a decrease lowest in the clinic-attending sub-group (p = 0.714
in London, p = 0.662 outside London). The disparity in trends between areas was
greatest among 45-59 year olds, with posterior probabilities of a decrease estimated to
be p = 0.990 in London, but only p = 0.681 outside London.
Due to small sample sizes, estimates of the number of PWID living with undiagnosed
HIV are uncertain, with low posterior probability (p = 0.26) of any decrease over 2012-
2017 (Table 1). For all heterosexuals, trends in the number of PLWH unaware of their
infection were similar for men and women (Figures 6 and 7 in the Appendix). Overall,
PLWH were an ageing population in 2012-2017, with the prevalent burden concentrated
in the 45-59 age group (Figure 8 of the Appendix).
4 Discussion
MSM, PWID and black African heterosexuals remain disproportionately affected by
undiagnosed HIV infection per population in 2017 (Table 1). However, we have demon-
strated remarkable decreases from 2012 to 2017 in the prevalence of HIV in these groups
and the first 90 of the UNAIDS 90-90-90 targets was met in 2016 among the population
aged 15-74 in England. The number of PLWH unaware of their infection halved to 6,900
(95% CrI 4,900 to 10,700) over the study period, with comparable reductions estimated
in all MSM and most black African heterosexual sub-groups. However, there are three
less encouraging findings from our analysis. First, the number undiagnosed outside Lon-
don is not decreasing as fast as in London. Second, trends in numbers undiagnosed were
too uncertain in other ethnicity heterosexuals who were not recent sexual health clinic
attendees to draw definitive conclusions. Finally, the numbers of recent clinic-attending
other ethnicity heterosexuals living with undiagnosed HIV are of comparable absolute
magnitude to those who had not recently attended a clinic. This implies many oppor-
tunities for testing are being missed in clinic attendees. Indeed, the latest PHE report
on HIV testing28 found that of eligible clinic attendees who were not either MSM, black
African or born in a high prevalence country, the proportion who were declining a HIV
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test had increased over the previous five years, to 27% in 2016.
This analysis used the most recent available datasets to provide estimates of the lat-
est trends in the HIV epidemic in England. A key strength of our MPES approach
is the continued and improved ability to estimate the unobserved burden of HIV, and
in particular, to quantify temporal changes, which are critical to prioritising policies
and monitoring progress towards HIV elimination8–11. Our estimates rely on model
assumptions necessary to identify unobservable quantities, including: relating undiag-
nosed prevalence to the proportion of HIV tests giving new diagnoses; and smoothing
constraints to address data sparsity. These assumptions are judged plausible, partic-
ularly as robustness is ensured by appropriately allowing for uncertainty: an example
is the modelling of the dynamic nature of prevalence estimated from the sexual health
clinic data within each year, assumed to lie between start- and end-year prevalences.
A consequence of both the epidemic and available data sources evolving over time is the
continuing adaptation of the MPES model. One outstanding issue is that the opiate-
using population, including PWID, is thought to be an ageing population29, so that
the age-gender distribution assumed may be outdated. However, given the low and
uncertain estimates of absolute numbers of PLWH among PWID, our estimates are
relatively robust to this ageing. Changes in migration and other population patterns
may also have occurred such that group sizes have changed since the ONS Census and
the NATSAL survey were carried out in 2011. Newer data sources are therefore being
sought to supplement the evidence base in more recent years, with accompanying model
development to make better, more efficient use of existing and new data sources. This
ongoing work includes: a new round of the NATSAL survey in 2020/21 (www.natsal.
ac.uk/online-consultation/background-to-natsal-4.aspx); updating estimates of
the PWID population size; incorportion of information from community and online
surveys30;31; and extending the MPES model to datasets collected by the other UK
nations.
Other approaches have been used to estimate trends in the number of undiagnosed HIV
infections in the UK. First, the CD4-staged “back-calculation” approach32;33, also a
Bayesian evidence synthesis, based on different data sources, is used annually to esti-
mate and monitor HIV incidence in MSM6. The corresponding estimates of the number
undiagnosed are consistent with our MPES estimates and both approaches provide com-
plementary pictures of the HIV epidemic in MSM in England. Another approach is
transmission modelling34;35, aimed at forecasting both the epidemic and the effects of
different possible interventions, particularly in the MSM population . Estimates of the
number of PLWH resulting from these transmission models are broadly consistent with
our estimates. The UNAIDS EPP/Spectrum software for estimating HIV prevalence,
incidence and mortality curves36 , are also based on modelling transmission and demo-
graphic dynamics, but in contrast to the MPES approach, do not provide estimates of
undiagnosed HIV prevalence.
Our estimates have important implications for efforts to eliminate HIV transmission in
England, especially the challenge of diagnosing HIV infections in other ethnicity het-
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erosexuals. Compared to black African heterosexuals, there are now probably more
undiagnosed HIV infections in other ethnicity heterosexuals, especially so outside of
London. Moreover, the rate of decrease of undiagnosed HIV infections in other ethnicity
heterosexuals who are not recent sexual health clinic attendees is the slowest of all. This
might be expected, given members of this population sub-set may have no particular
reason to consider themselves at HIV risk – if they did, then they could be expected to
attend a clinic for a test. On the other hand, since undiagnosed HIV prevalence in other
ethnicity heterosexuals who are recent clinic attendees is almost 40 times greater than
in those who are not (Table 2), the priority must be to ensure all of these have an HIV
test, rather than the 27% that currently do so28. As all clinic attendees living with HIV
become diagnosed, improved partner notification37 is likely to accelerate reducing the
undiagnosed fraction in the wider population, making the prospect of HIV elimination
increasingly likely.
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